Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram

scientific article published on 17 October 2013

Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1517/14740338.2013.840583
P698PubMed publication ID24131458

P2093author name stringChangsu Han
Chi-Un Pae
Prakash S Masand
Sheng-Min Wang
Soo-Jung Lee
Ashiwn A Patkar
P2860cites workAnalysis of suspected suicides using poison center dataQ23921390
QT interval and antidepressant use: a cross sectional study of electronic health recordsQ24629713
Toxicology and overdose of atypical antipsychoticsQ28265894
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomerQ28320942
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorderQ31121208
Drug-induced prolongation of the QT intervalQ33151147
Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderlyQ33158076
Assessing QT interval prolongation and its associated risks with antipsychotics.Q33160123
Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control studyQ33632295
Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdoseQ33820358
National trends in psychotropic medication polypharmacy in office-based psychiatryQ34090959
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.Q34342685
Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdoseQ34347727
Evaluation of a QT nomogram for risk assessment after antidepressant overdose.Q34457439
Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohortQ34587359
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelinesQ34590507
Antipsychotic-related QTc prolongation, torsade de pointes and sudden deathQ34730759
What Clinicians Should Know About the QT IntervalQ35112554
Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdosesQ35827376
Clinical use of antidepressant therapy and associated cardiovascular riskQ36184863
The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applicationsQ36512947
Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram.Q36946346
Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance databaseQ37152047
Electrophysiological changes of cardiac function during antidepressant treatmentQ37362668
A comparative study of non-fatal self-poisoning with antidepressants relative to prescribing in three centres in EnglandQ37623169
Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?Q38022815
Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdoseQ39095473
Sertindole causes distinct electrocardiographic T-wave morphology changesQ39885611
The effect of sertindole on QTD and TPTE.Q39915573
Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants.Q40283029
Tricyclic antidepressants in depressed patients with cardiac conduction diseaseQ42224094
Torsade de Pointes Episodes under Treatment with Selective Serotonin Reuptake InhibitorsQ42867714
Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramineQ43138457
hERG K+ channel-associated cardiac effects of the antidepressant drug desipramineQ43487048
Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patientsQ43690649
Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000.Q44710932
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibitionQ44717873
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currentsQ45711433
QTc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors.Q46024543
Exposure to antidepressant medications and suicide attempts in adult depressed inpatientsQ46645215
The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approachQ46819442
Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study.Q48681357
Use of an integrated mercury food web model for ecological risk assessment.Q51196700
Reconciling the risk of QT interval prolongation in antidepressants.Q54484056
P433issue2
P407language of work or nameEnglishQ1860
P304page(s)197-205
P577publication date2013-10-17
P1433published inExpert Opinion on Drug SafetyQ5421206
P1476titleAntidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram
P478volume13

Reverse relations

cites work (P2860)
Q47346313Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials
Q33662939Effects of Escitalopram on Anxiety in Patients with Acute Coronary Syndrome: A Randomized Controlled Trial
Q35754726Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
Q47604739Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement
Q38536162Treating OCD: what to do when first-line therapies fail

Search more.